CLDF Title
Home | Contact Us | Bookmark
About CLDF Centers of Educational Expertise  
Live CME Meetings Webcasts Slide Library Abstract Library Conference Highlights
Reuters Health Information (2013-03-26): Integrated psych care for high-risk hep C patients may increase antiviral treatment


Integrated psych care for high-risk hep C patients may increase antiviral treatment

Last Updated: 2013-03-26 13:24:10 -0400 (Reuters Health)

NEW YORK (Reuters Health) - Hepatitis C patients who have psychiatric disorders and problems with substance abuse may benefit from integrated care, a new study has found.

More patients in integrated care began antiviral treatment and achieved a sustained viral response in a trial of 365 patients at three Veterans Affairs medical centers, according to research presented March 20th at the annual meeting of the Society of Behavioral Medicine in San Francisco by Dr. Erick Groessl and a team at the University of California, San Diego and VA San Diego.

"This is just the kind of smart study that addresses the heightened focus in healthcare on identifying interventions that will really work in the real world," said Dr. Kathy Goggin, a psychologist at the University of Missouri-Kansas City who was not involved in the study.

In email to Reuters Health, she added, "Reducing patient burden while improving outcomes is good for everyone and will likely lead to significant cost savings."

The research team screened 1167 patients at the three HCV clinics. Of these, 65% were eligible for antiviral treatment and had psychiatric and/or substance use risk factors. Ultimately, 365 patients were randomized to either integrated care or usual care.

In this high-risk cohort, 51% were homeless at some point five years before treatment, 50.4% were risk-positive for post-traumatic stress disorder, and the mean Beck Depression Index score was 15.34, which indicates mild depression.

Patients who were randomized to receive integrated care were 1.6 times more likely to initiate antiviral therapy at all three treatment centers, at 32.4% compared to 19.7% (p=0.006).

More than twice as many patients achieved a sustained viral response in the integrated-care group, at 24 patients compared to 11 (13.2% vs 6.0%; p=0.016). "It is very important to remember that this is the SVR rate among all people randomized for the study," Dr. Groessl told Reuters Health. "That rate is a function of percent treated and the SVR rate among those treated." For example, he said, 59 patients in the integrated care group were treated, and their SVR rate was roughly 40%. In the usual care group, 36 patients were treated, and their SVR rate was roughly 30%.

There were also fewer deaths in the integrated-care group, at six, compared to 11 in the usual-care group (3.3% vs 6.0%; p=0.022).

"This model has been studied at three VA sites, so we plan to study the implementation of the program at additional VA sites and non-VA sites in the near future," Dr. Groessl said.

Possible barriers to the future adoption of this model of care may be inherent organizational differences at different health care centers and also the potential need for new funding for clinical staff. "We will address both of these factors in our planned implementation study," Dr. Groessl said.

Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Live CME Meetings
Slide Library
Abstract Library
Slide Library
Abstract Library
CLDF Follow Us
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
Centers of
Educational Expertise
Substance Use Disorder
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2016 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.